• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Pacific Biosciences of California Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    6/6/25 4:21:08 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $PACB alert in real time by email
    pacb-20250604
    0001299130false00012991302025-06-042025-06-04

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549
    FORM 8-K
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of
    The Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported)
    June 4, 2025
    Pacific Biosciences of California, Inc.
    (Exact name of registrant as specified in its charter)
    Delaware001-3489916-1590339
    (State or other jurisdiction
    of incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)
    1305 O’Brien Drive
    Menlo Park, California 94025
    (Address of principal executive offices) (Zip Code)
    (650) 521-8000
    (Registrant’s telephone number, including area code)
    (Former name or former address, if changed since last report)
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
    oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, par value $0.001 per sharePACBThe NASDAQ Stock Market LLC
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company o
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



    ITEM 5.02.    DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
    On April 22, 2025, the board of directors (the "Board") of Pacific Biosciences of California, Inc. (the “Company”), at the recommendation of the compensation committee of the Board, approved an amendment (the “Amendment”) to the Company’s 2020 Equity Incentive Plan (the “2020 Plan”), subject to stockholder approval, to reserve an additional 23,000,000 shares of the Company’s common stock (the “Additional Shares”) for issuance pursuant to the 2020 Plan. As described below under Item 5.07, the stockholders of the Company approved the Amendment at the annual meeting of stockholders held virtually on June 4, 2025 (the “Annual Meeting”).
    A more complete description of the material terms of the Amendment and 2020 Plan can be found in “Proposal 4: Approval of Amendment to the 2020 Equity Incentive Plan” in the Company’s definitive proxy statement originally filed with the Securities and Exchange Commission (“SEC”) on April 23, 2025 (as supplemented, the “Proxy Statement”), which description is incorporated by reference herein. The foregoing descriptions and the descriptions incorporated by reference from the Proxy Statement are qualified by reference to the full text of the 2020 Plan, as amended, a copy of which is filed as Exhibit 10.1 to this report and incorporated by reference herein.
    ITEM 5.07.    SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
    The Company held the Annual Meeting on June 4, 2025. Of the 300,041,319 shares of the Company’s common stock outstanding as of 5:00 p.m. (Pacific time) on April 10, 2025, the record date for the Annual Meeting, 186,123,123 shares were represented at the Annual Meeting, either by virtual attendance or by proxy, constituting approximately 62% of shares of common stock entitled to vote at the Annual Meeting. The four matters voted on at the Annual Meeting and the voting results with respect to each such matter are set forth below:
    Proposal 1: Election of Four Class III Directors
    Name of DirectorForAgainstAbstainBroker Non-Votes
    William Ericson104,132,46624,793,642809,85456,387,161
    Kathy Ordoñez126,729,2732,137,971868,71856,387,161
    Christopher M. Smith126,830,1612,076,866828,93556,387,161
    Each director nominee was duly elected to serve until the 2026 annual meeting of stockholders and until his or her successor is duly elected and qualified, subject to his or her earlier resignation or removal.
    Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm
    ForAgainstAbstainBroker Non-Votes
    162,154,84922,599,7391,368,535—
    The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
    Proposal 3: Advisory Vote on Approval of Named Executive Officer Compensation
    ForAgainstAbstainBroker Non-Votes
    78,367,53150,498,020870,41156,387,161
    The stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers.
    Proposal 4: Approval of Amendment to the 2020 Equity Incentive Plan
    ForAgainstAbstainBroker Non-Votes
    85,355,38243,563,859816,72156,387,161
    The stockholders approved the amendment to the 2020 Plan to increase the number of shares of the Company’s common stock reserved thereunder.



    ITEM 9.01.    FINANCIAL STATEMENTS AND EXHIBITS.
    (d)Exhibits.
    Exhibit No.Description
    10.1+*
    Pacific Biosciences of California, Inc. 2020 Equity Incentive Plan, as amended
    104Cover Page Interactive Data File (embedded within the Inline XBRL document)
    + Indicates management contract or compensatory plan.
    * Filed herewith.



    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    Pacific Biosciences of California, Inc.
    By:/s/ Brett Atkins
    Brett Atkins
    General Counsel
    Date: June 6, 2025

    Get the next $PACB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PACB

    DatePrice TargetRatingAnalyst
    11/11/2024Buy → Neutral
    UBS
    6/3/2024$4.00Buy
    Jefferies
    4/22/2024Overweight → Neutral
    JP Morgan
    4/18/2024$7.00 → $2.50Buy → Neutral
    Goldman
    12/14/2023$11.00Overweight
    Stephens
    12/14/2023Neutral
    Guggenheim
    12/13/2023Peer Perform
    Wolfe Research
    11/17/2023$13.00 → $10.00Neutral → Buy
    UBS
    More analyst ratings

    $PACB
    Leadership Updates

    Live Leadership Updates

    See more
    • PacBio Expands Distribution in China, Gaining Access to New Clinical Lab Networks via Haorui Gene

      MENLO PARK, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate sequencing solutions, today announced the appointment of Haorui Gene, a globally recognized leader in blood typing genomics, as an official distributor in China. The distribution arrangement is designed to expand access to PacBio's HiFi long-read sequencing technology in clinical and research settings, with a focus on transfusion medicine and hematology, areas where precision and completeness of genomic data are critical to patient outcomes. Founded in 2020, Haorui Gene has quickly become a key player in blood typing genomics, deploying seven Sequel II and three R

      5/22/25 9:05:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Jim Gibson to join PacBio as Chief Financial Officer

      MENLO PARK, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced Jim Gibson will join and be appointed as the company's new Chief Financial Officer, effective as of his start date, which is expected to be March 31, 2025. With over three decades of financial leadership experience at some of Silicon Valley's most iconic and innovative companies, Mr. Gibson brings a deep track record of operational excellence, strategic financing, and scaling global organizations. Mr. Gibson joins PacBio from Sequoia, a strategic compensation and benefits solutions provider, where he served as CFO across

      3/27/25 9:05:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Service

      MENLO PARK, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Ruggiero as the company's new Global Head of Sales & Service. Mr. Ruggiero brings over two decades of experience in sales leadership within the technology and life sciences sectors. Prior to joining PacBio, he served as Senior Vice President, North America for Sinch AB, a leading global provider of cloud-based communication solutions for business and mobile operators. In his role he led North American sales for the enterprise, mid-market segments. Before that, he held senior sales positions at Zoom V

      2/3/25 9:05:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PACB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date

      Organization's 6,000-genome effort will power global ALS research through detailed long-read sequencing data made freely available to scientists worldwide NEW YORK and MENLO PARK, Calif., June 2, 2025 /PRNewswire/ -- Target ALS, a nonprofit breaking down barriers to amyotrophic lateral sclerosis (ALS) research, has partnered with PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate long read sequencing platforms, to launch the largest global whole genome sequencing initiative for ALS to date. By applying PacBio's HiFi sequencing to more than 6,000 genomes from people with ALS and healthy controls, the project aims to detect structural variants, repeat expansions, and ot

      6/2/25 10:00:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio to Present at Upcoming Investor Conferences

      MENLO PARK, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences: Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 8:45 AM ET in New York, NY46th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 11, 2025, at 10:40 AM ET in Miami Beach, FL Live webcasts of the events can be accessed at the company's investors page at investor.pacificbiosciences.com. A replay of the webcasts will be available for at least 30 days following the event. About PacBio PacBio (NASDAQ:PACB

      5/28/25 9:00:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio Expands Distribution in China, Gaining Access to New Clinical Lab Networks via Haorui Gene

      MENLO PARK, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate sequencing solutions, today announced the appointment of Haorui Gene, a globally recognized leader in blood typing genomics, as an official distributor in China. The distribution arrangement is designed to expand access to PacBio's HiFi long-read sequencing technology in clinical and research settings, with a focus on transfusion medicine and hematology, areas where precision and completeness of genomic data are critical to patient outcomes. Founded in 2020, Haorui Gene has quickly become a key player in blood typing genomics, deploying seven Sequel II and three R

      5/22/25 9:05:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PACB
    SEC Filings

    See more
    • Pacific Biosciences of California Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

      6/6/25 4:21:08 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SD filed by Pacific Biosciences of California Inc.

      SD - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

      5/29/25 4:06:12 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEFA14A filed by Pacific Biosciences of California Inc.

      DEFA14A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

      5/20/25 5:26:51 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PACB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Pacific Biosciences downgraded by UBS

      UBS downgraded Pacific Biosciences from Buy to Neutral

      11/11/24 9:44:33 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Jefferies resumed coverage on Pacific Biosciences with a new price target

      Jefferies resumed coverage of Pacific Biosciences with a rating of Buy and set a new price target of $4.00

      6/3/24 8:16:36 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Pacific Biosciences downgraded by JP Morgan

      JP Morgan downgraded Pacific Biosciences from Overweight to Neutral

      4/22/24 7:40:44 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PACB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $PACB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $PACB
    Financials

    Live finance-specific insights

    See more
    • Meline David W bought $176,160 worth of shares (40,000 units at $4.40) (SEC Form 4)

      4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

      3/6/24 5:36:07 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Director Mohr Marshall

      4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

      6/6/25 4:10:59 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Director Livingston Randall S

      4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

      6/6/25 4:10:13 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 4 filed by Director Ordonez Kathy

      4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

      6/6/25 4:09:30 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio Announces First Quarter 2025 Financial Results

      MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter ended March 31, 2025. First quarter results:  Q1 2025Q1 2024Revenue$37.2 million$38.8 millionInstrument revenue$11.0 million$19.0 millionConsumable revenue$20.1 million$16.0 millionService and other revenue$6.0 million$3.8 millionRevio™ systems1228Vega™ systems28—Annualized Revio pull-through per system~$236,000~$254,000Cash, cash equivalents, and investments$343.1 million$561.9 million Gross margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the correspon

      5/8/25 4:15:34 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio Announces Preliminary First Quarter 2025 Revenue and Reiterates 2025 Revenue Guidance of $155 Million to $170 Million

      Implements Plan to Reduce Annualized Operating Expense Run Rate by $45 Million to $50 Million Q1 2025 Earnings Conference Call Scheduled for May 8, 2025 MENLO PARK, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2025. Preliminary First Quarter Results  Preliminary Q1 2025Q1 2024Revenue$36.9 million$38.8 millionInstrument revenue$10.8 million$19.0 millionConsumable revenue$20.1 million$16.0 millionService and other revenue$6.0 million$3.8 millionRevio systems1228Vega systems28-Annualized Revio pull-through per system~$236,000~$254,000Cash, cash equivalents, and investments$343.1 million$561.9

      4/9/25 9:05:00 AM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results

      MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Fourth quarter results Revenue of $39.2 million, a 33% decrease compared with $58.4 million in the prior-year period.Instrument revenue of $15.3 million compared with $35.1 million in the prior-year period. Instrument revenue in the fourth quarter of 2024 included 23 Revio® sequencing systems and 7 Vega™ sequencing systems.Consumables revenue of $18.8 million compared with $18.9 million in the prior-year period.Service and other revenue of $5.1 million compared with $4.4 million in the prior-year period. Gross margin, opera

      2/13/25 4:05:00 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $PACB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Pacific Biosciences of California Inc.

      SC 13G - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

      11/26/24 8:27:01 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Pacific Biosciences of California Inc.

      SC 13G - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

      11/14/24 5:52:54 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Pacific Biosciences of California Inc.

      SC 13G/A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

      11/14/24 5:48:11 PM ET
      $PACB
      Biotechnology: Laboratory Analytical Instruments
      Industrials